lcl161
Plasma Cell Myeloma
Novartis PharmaceuticalsPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 59/ 100
Competitive context
475 Active assets in the Plasma Cell Myeloma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hyaluronidase fihj Massachusetts General Hospital | Phase 4 | BBB |
Filanesib PETHEMA Foundation | Phase 2 | BBB |
CYCLOSPORIN A Seoul National University Hospital | Phase 3 | BBB |
VINCRISTINE SULFATE Roswell Park Cancer Institute | Phase 3 | BBB |
Anti-Thymoglobulin, Rabbit University of Birmingham | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
lcl161 is also rated in:
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell CarcinomaDormant
CC
Indicative ·
47 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →